ClinicalTrials.gg
CompletedNCT07081958Updated Nov 12, 2026

A Study Evaluating the Effect of Daily Oral Tifeglipron (RO7795081) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

A Phase 2 interventional study of Tifeglipron and Placebo in Obesity or Overweight, sponsored by Hoffmann-La Roche. Completed at 36 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Updated Nov 12, 2026Interventions changedTitle changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
352
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Obesity by Hoffmann-La Roche — 8 open to participants now, 12 under way, 7 of them phase 3. Obesity · Hoffmann-La Roche.

Enrollment
10th of 21
352 · median 300
Started
2025
with 3 others
Phase 2
7 of 21
1 open now
Registered
11th of 21
by date

Among the 21 studies in Obesity by Hoffmann-La Roche, this one is the 10th largest by enrollment, is one of 4 that started in 2025, is one of 7 in phase 2, and was the 11th registered.

Obesity

11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

Browse Obesity studies →

Open to participants now

8 of the 21 studies in Obesity by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,343 Obesity studies recruiting now, 377 (28%) set no upper age limit and 862 (64%) stop at 75 or younger; 168 take children under 18; 488 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Obesity by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of tifeglipron (RO7795081) for chronic weight management in adult participants with obesity or overweight with at least one weight-related comorbidity, but without diabetes mellitus.

03

Conditions studied

  • Obesity or Overweight
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have at screening:

    1. (BMI) greater than or equal to (≥)30.0 kg/m\^2; or
    2. BMI ≥27.0 kg/m\^2 and \<30.0 kg/m\^2 with at least one weight-related comorbidity, such as hypertension, dyslipidemia, diagnosis of obstructive sleep apnea, cardiovascular disease
  • History of ≥1 self-reported unsuccessful diet/exercise effort to lose body weight
  • A stable body weight for the 3 months prior to screening (maximum 5% body weight gain and/or loss)

Exclusion criteria

Exclusion Criteria:

  • Have a history or diagnosis of any type of diabetes mellitus (Type 1 diabetes [T1D], T2D, or rare forms of diabetes)
  • Have obesity induced by other endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., melanocortin-4 receptor deficiency or Prader-Willi Syndrome)
  • Participation in unbalanced/extreme diets or in an organized weight reduction program within 3 months of the screening visit or planning to engage in such diets or programs during the study
  • Prior or planned surgical treatment for obesity
  • Have a known, gastric emptying abnormality
  • Have poorly controlled hypertension, untreated renal artery stenosis, or evidence of labile blood pressure including symptomatic postural hypotension
  • Have any of the following cardiovascular conditions within 3 months prior to screening: Acute myocardial infarction; Cerebrovascular accident (stroke)/; Unstable angina; Hospitalization due to congestive heart failure.
  • Have a history of acute or chronic pancreatitis
  • Have a history of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder (e.g., schizophrenia, bipolar disorder, or other serious mood or anxiety disorder), or had a suicide attempt within the last 1 year of screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
352 participants (actual)

Study arms

  • Placebo comparator
    Arm 1: Placebo

    Drug: Placebo

  • Experimental
    Arm 2: Tifeglipron Dosing Regimen 1

    Drug: Tifeglipron

  • Experimental
    Arm 3: Tifeglipron Dosing Regimen 2

    Drug: Tifeglipron

  • Experimental
    Arm 4: Tifeglipron Dosing Regimen 3

    Drug: Tifeglipron

  • Experimental
    Arm 5: Tifeglipron Dosing Regimen 4

    Drug: Tifeglipron

  • Experimental
    Arm 6: Tifeglipron Dosing Regimen 5

    Drug: Tifeglipron

  • Experimental
    Arm 7: Tifeglipron Dosing Regimen 6

    Drug: Tifeglipron

  • Experimental
    Arm 8: Tifeglipron Dosing Regimen 7

    Drug: Tifeglipron

Interventions

  • Tifeglipron will be administered orally once daily, according to the randomized dosing regimen, during the 38-week treatment period.

    Also known as: RO7795081, CT-996, RG6652

  • DrugPlacebo

    Placebo matching each tifeglipron dosing regimen arm will be administered orally once daily during the 38-week treatment period.

06

What researchers measure

Primary outcomes

  1. Percent Change in Body Weight From Baseline to Week 30

    Time frame: Baseline to Week 30

Secondary outcomes

  1. Absolute Change in Body Weight (kg) from Baseline to Week 30

    Time frame: Baseline to Week 30

  2. Absolute Change in Body Weight (kg) from Baseline to Week 38

    Time frame: Baseline to Week 38

  3. Percent Change in Body Weight From Baseline to Week 38

    Time frame: Baseline to Week 38

  4. Percentage of Participants Who Achieve ≥5%, ≥10%, ≥15%, or ≥20% Body Weight Reduction from Baseline at Week 30

    Time frame: Baseline and Week 30

  5. Percentage of Participants Who Achieve ≥5%, ≥10%, ≥15%, or ≥20% Body Weight Reduction from Baseline at Week 38

    Time frame: Baseline and Week 38

  6. Absolute Change in BMI (kg/m^2) from Baseline to Week 30

    Time frame: Baseline to Week 30

  7. Absolute Change in BMI (kg/m^2) from Baseline to Week 38

    Time frame: Baseline to Week 38

  8. Incidence of Adverse Events (AEs), Adverse Events of Special Interest (AESIs), and Serious AEs (SAEs)

    Time frame: From first dose until 28 days after the final dose of study treatment (42 weeks)

  9. Change in Columbia-Suicide Severity Rating Scale (C-SSRS) Scores from Baseline to Week 42

    The C-SSRS is an assessment tool to evaluate suicidal ideation and behavior during the assessment period via a participant-reported questionnaire comprising 2 to 6 questions (yes or no). Affirmative responses count as 1 point, which are then summed to indicate the level of suicide risk on a scale of 0 (no risk) to 6 (high risk).

    Time frame: Baseline to Week 42

  10. Change in Patient Health Questionnaire-9 (PHQ-9) Scores from Baseline to Week 42

    PHQ-9 is a 9-item patient reported outcome (PRO) used to assess severity of depression. Responses are rated based on the frequency of symptoms on a 4-point Likert scale, ranging from 0 (not at all) to 3 (nearly every day). A PHQ-9 total score ranging from 0 to 27 can be calculated by summing the nine items; a higher score corresponds with more severe depression.

    Time frame: Baseline to Week 42

  11. Plasma Concentrations of Tifeglipron at Prespecified Timepoints

    Time frame: Predose on Day 1 and at prespecified timepoints until Week 38

07

Study locations

36 sites
  • Pinnacle Research Group
    Anniston, Alabama 36207, United States
  • Orange County Research Center
    Lake Forest, California 92630, United States
  • Prospective Research Innovations Inc.
    Rancho Cucamonga, California 91730, United States
  • Asclepes Research Centers
    Sherman Oaks, California 91403, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • Chase Medical Research
    Waterbury, Connecticut 06708-3346, United States
  • Emerson Clinical Research Institute LLC
    Washington D.C., District of Columbia 20009, United States
  • K2 Medical Research-Winter Garden
    Clermont, Florida 34711, United States
  • K2 Medical Research-Maitland
    Maitland, Florida 32751, United States
  • Rophe Adult and Pediatric Medicine/SKYCRNG
    Union City, Georgia 30291, United States
  • Accellacare of Duly Health and Care
    Oak Lawn, Illinois 60453, United States
  • Accellacare of McFarland
    Ames, Iowa 50010, United States
  • Mercury Street Medical Group, PLLC
    Butte, Montana 59701, United States
  • Neurobehavioral Research, Inc.
    Cedarhurst, New York 11516, United States
  • Accellacare of Cary - Cary Medical Group
    Cary, North Carolina 27518, United States
  • Accellacare - Hickory
    Hickory, North Carolina 28601, United States
  • Accellacare of Raleigh
    Raleigh, North Carolina 27609, United States
  • Accellacare of Rocky Mount
    Rocky Mount, North Carolina 27804, United States
  • Accellacare of Salisbury
    Salisbury, North Carolina 28144, United States
  • Accellacare of Piedmont Healthcare
    Statesville, North Carolina 28625, United States
  • Accellacare of Wilmington, LLC
    Wilmington, North Carolina 28401, United States
  • Accellacare Research of Winston Salem
    Winston-Salem, North Carolina 27103, United States
  • Alliance for Multispecialty Research, LLC (AMR Norman)
    Norman, Oklahoma 73069, United States
  • Tristar Clinical Investigations
    Philadelphia, Pennsylvania 19114, United States
  • Internal Medicine and Pediatrics Associates of Bristol
    Bristol, Tennessee 37620, United States
  • Alliance for Multispecialty Research. LLC
    Knoxville, Tennessee 37909, United States
  • Accellacare of Knoxville
    Knoxville, Tennessee 37912, United States
  • Knoxville-Summit-Halls Family Practice
    Knoxville, Tennessee 37938, United States
  • Clinical Research Associates
    Nashville, Tennessee 37203, United States
  • Texas Diabetes & Endocrinology, P.A.
    Austin, Texas 78731, United States
  • Apex Mobile Clinical Research
    Bellaire, Texas 77401, United States
  • Velocity Clinical Research
    Dallas, Texas 75230, United States
  • Juno Research, LLC
    Houston, Texas 77040, United States
  • Consano Clinical Research
    Shavano Park, Texas 78231, United States
  • Chrysalis Clinical Research
    St. George, Utah 84790, United States
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Apr 2026, 8 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 8 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2025
First posted
Jul 24, 2025
StartActual
Jul 29, 2025
Primary completionActual
Apr 28, 2026
CompletionActual
Jul 30, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Accellacare of McFarland · Ames, United States
Show 1 removed
  • McFarland Clinic under Accellacare · Ames, United States
Oct 26, 2026
Interventions
Changed RO7795081→Tifeglipron. Arm changed Arm 2: RO7795081 Dosing Regimen 1→Arm 2: Tifeglipron Dosing Regimen 1; Arm 3: RO7795081 Dosing Regimen 2→Arm 3: Tifeglipron Dosing Regimen 2; Arm 4: RO7795081 Dosing Regimen 3→Arm 4: Tifeglipron Dosing Regimen 3; Arm 5: RO7795081 Dosing Regimen 4→Arm 5: Tifeglipron Dosing Regimen 4; Arm 6: RO7795081 Dosing Regimen 5→Arm 6: Tifeglipron Dosing Regimen 5; Arm 7: RO7795081 Dosing Regimen 6→Arm 7: Tifeglipron Dosing Regimen 6; Arm 8: RO7795081 Dosing Regimen 7→Arm 8: Tifeglipron Dosing Regimen 7
Nov 12, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedPlasma Concentrations of RO7795081Tifeglipron at Prespecified TimepointsTime frame: Predose on Day 1 and at prespecified timepoints until Week 38
Nov 12, 2026
Title
A Study Evaluating the Effect of Daily Oral Tifeglipron (RO7795081) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedPlasma Concentrations of RO7795081Tifeglipron at Prespecified TimepointsTime frame: Predose on Day 1 and at prespecified timepoints until Week 38
    Interventions Changed RO7795081→Tifeglipron. Arm changed Arm 2: RO7795081 Dosing Regimen 1→Arm 2: Tifeglipron Dosing Regimen 1; Arm 3: RO7795081 Dosing Regimen 2→Arm 3: Tifeglipron Dosing Regimen 2; Arm 4: RO7795081 Dosing Regimen 3→Arm 4: Tifeglipron Dosing Regimen 3; Arm 5: RO7795081 Dosing Regimen 4→Arm 5: Tifeglipron Dosing Regimen 4; Arm 6: RO7795081 Dosing Regimen 5→Arm 6: Tifeglipron Dosing Regimen 5; Arm 7: RO7795081 Dosing Regimen 6→Arm 7: Tifeglipron Dosing Regimen 6; Arm 8: RO7795081 Dosing Regimen 7→Arm 8: Tifeglipron Dosing Regimen 7
    Title A Study Evaluating the Effect of Daily Oral Tifeglipron (RO7795081) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
    + 2 other changes: verification date and description
  2. Oct 26, 2026
    1 site added, 1 site removed
    Show site
    • Accellacare of McFarland · Ames, United States
    Show 1 removed
    • McFarland Clinic under Accellacare · Ames, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07081958
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 24, 2025
Start date
Jul 29, 2025
Primary completion
Apr 28, 2026
Completion
Jul 30, 2026
Last update
Nov 12, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tifeglipron

Start the discussion